NEW YORK: The US on Thursday authorized Merck & Co’s antiviral pill for COVID-19 for certain high-risk adult patients, a day after giving the go-ahead to a similar but more effective treatment from Pfizer Inc. Merck’s drug, molnupiravir developed with Ridgeback Biotherapeutics, was shown to reduce hospitalizations and deaths by around 30% in a clinical trial of high-risk individuals early in the course of the illness.
The U.S. Food and Drug Administration authorized Merck’s drug to treat mild-to-moderate COVID-19 in adults who are at risk for severe disease, and for whom alternative COVID-19 treatments are not accessible or clinically appropriate.
Pfizer’s drug, Paxlovid was authorized on Wednesday for people aged 12 and older and has shown to be nearly 90% effective in preventing hospitalizations and deaths in patients at high risk of severe illness, according to trial data.
The Pfizer treatment’s two-drug regimen may not be appropriate for some patients because it includes an older antiviral called ritonavir that is known to have interactions with some other prescription medicines.
Comments
Comments are closed for this article.